**Strong critical reception and robust pre-release tracking position the under-$70 million bracket as the clear market leader at 62.5% implied probability.** Zach Cregger’s fresh reboot of the Resident Evil franchise has earned near-universal praise (96% on Rotten Tomatoes), including standout audience scores, for its tight 95-minute runtime, video game-inspired thrills, and Austin Abrams-led cast. This buzz, combined with Cregger’s recent horror success on *Weapons*, has driven record franchise previews of $8–9 million and pushed third-party estimates to $40–50 million domestically, with some optimistic trackers eyeing a possible $50–60 million ceiling. Sony’s own projection sits at roughly $40 million from about 3,500 theaters on a $75 million budget, comfortably ahead of the prior franchise high of $26.6 million (*Afterlife*, 2010). Limited weekend competition and positive word-of-mouth potential further support momentum within the $40–60 million range. The higher brackets (70M+) carry lower implied odds because even bullish scenarios remain well below those thresholds, though late surges in turnout or exceptional holds could narrow the gap. Traders are pricing in the film’s genre constraints and historical precedent for horror openings while recognizing the unusually strong early indicators for this IP revival.